{"created":"2021-03-01T06:10:20.568922+00:00","id":6436,"links":{},"metadata":{"_buckets":{"deposit":"bf32dfda-f5f0-4cf8-a4f0-0fb1dd9fd15d"},"_deposit":{"id":"6436","owners":[],"pid":{"revision_id":0,"type":"depid","value":"6436"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00006436","sets":["453:456","471:537:568:619"]},"item_7_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1996-06","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"86","bibliographicPageStart":"79","bibliographicVolumeNumber":"44","bibliographic_titles":[{"bibliographic_title":"Acta medica et biologica"},{"bibliographic_title":"Acta medica et biologica","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Cis-diamminedichloroplatinum (II) (CDDP) resistant-human ovarian cancer cell line (TYK-R10) was examined for its drug resistance to other anti-cancer drugs, and growth response to various growth factors, compared with the parental cell line (TYK-nu). TYK-R10 was established by a gradual increase in the concentrations of CDDP compared with the parental line. TYK-R10 showed about a ten-fold resistance, with 1×10^<-5> M CDDP of IC_<50>, which represents the concentration of an anti-cancer drug to produce a 50% inhibition of cell growth. TYK-R10 revealed a cross resistance to various anti-cancer drugs including carboplatin (CBDCA), vincristin (VCR) and adriamycin (ADR). However, no significant alternations in topoisomerase II, glutathione-S-transferase levels or glutathione concentrations were detected. In addition, P-glycoprotein (P-gp) was not expressed on the cell surface of TYK-R10 and verapamil had no reverse effect on resistance to CDDP, CBDCA, VCR and ADR. Surface marker analysis using epidermal growth factor receptor antibody disclosed a high positivity in TYK-R10, compared with TYK-nu, and consequently epidermal growth factor activated the growth of TYK-R10. Transforming growth factor α had no effect on the growth of TYK-R10, whereas it promoted the growth of TYK-nu. In contrast, transforming growth factor β promoted the growth of TYK-nu, whereas it inhibited the growth of TYK-R10. These results indicate that the mechanism of multidrug resistance of TYK-R10 is not mediated through P-gp, and that altered responsibility for some growth factor in TYK-R10 is closely associated with the acquisition of CDDP resistance.","subitem_description_type":"Abstract"}]},"item_7_publisher_7":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Niigata University School of Medicine"}]},"item_7_select_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_7_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA00508361","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"05677734","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kamishima, Tomoko"}],"nameIdentifiers":[{"nameIdentifier":"52917","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-06"}],"displaytype":"detail","filename":"44(2)_79-86.pdf","filesize":[{"value":"1.0 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"44(2)_79-86.pdf","url":"https://niigata-u.repo.nii.ac.jp/record/6436/files/44(2)_79-86.pdf"},"version_id":"226ee824-1575-4951-8223-3478b394589f"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"cisplatin","subitem_subject_scheme":"Other"},{"subitem_subject":"multidrug resistance","subitem_subject_scheme":"Other"},{"subitem_subject":"growth factors","subitem_subject_scheme":"Other"},{"subitem_subject":"ovarian cancer cell line","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Characteristic Cross Resistance to Anti-Cancer Drugs and Different Responses for Various Growth Factors in Cisplatin Resistant-Human Ovarian Cancer Cell Line (TYK-R10)","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Characteristic Cross Resistance to Anti-Cancer Drugs and Different Responses for Various Growth Factors in Cisplatin Resistant-Human Ovarian Cancer Cell Line (TYK-R10)"},{"subitem_title":"Characteristic Cross Resistance to Anti-Cancer Drugs and Different Responses for Various Growth Factors in Cisplatin Resistant-Human Ovarian Cancer Cell Line (TYK-R10)","subitem_title_language":"en"}]},"item_type_id":"7","owner":"1","path":["456","619"],"pubdate":{"attribute_name":"公開日","attribute_value":"2015-08-27"},"publish_date":"2015-08-27","publish_status":"0","recid":"6436","relation_version_is_last":true,"title":["Characteristic Cross Resistance to Anti-Cancer Drugs and Different Responses for Various Growth Factors in Cisplatin Resistant-Human Ovarian Cancer Cell Line (TYK-R10)"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2022-12-15T04:31:31.620470+00:00"}